The North America Vitrification Market would witness market growth of 16.8% CAGR during the forecast period (2023-2030).
Embryos and eggs are preserved for future use through vitrification when frozen. Techniques for vitrifying cells and tissues help preserve them, and they have a variety of applications in reproductive biology or regenerative medicine. It is employed, among other things, in preserving human fertility, storing cells for cell therapy, tissue regeneration, and gamete and embryo banking.
The need for assisted reproductive technologies (ARTs), a greater understanding of reproductive health issues, and an increase in service providers providing vitrification services are all expected to fuel the expansion of the market. This cryopreservation approach has become more effective because of its advantages over traditional slow-cooling methods. Additionally, given the current situation, most IVF facilities choose it because of its dependability and higher output.
The improvement of methods for preserving fertility sparked the creation of vitrification. This cutting-edge technique offers specimen preservation alternatives by reducing cryoprotectant exposure and shortening the preservation period. As a result, the market has seen profitable revenue growth. This has increased the widespread usage of vitrification devices. Delaying parenting is generally associated with sociodemographic factors, such as career and educational objectives, the growing influence of women's empowerment campaigns, the absence of a spouse, and financial constraints.
The Census Bureau said that between 1990 and 2019, the fertility rates in the United States steadily decreased. There were roughly 70.77 births per year for every 1,000 women aged between 15 to 44 in 1990. In that age group in 2019, there were approximately 58.21 births per 1,000 women. Further, the statistics showed that throughout the roughly 30-year period, the fertility rates of women aged 20 to 24 decreased by 43%, while those aged 35 to 39 soared by 67%. The AHR Act accomplishes this by outlining prohibited acts linked to aided human reproduction that could pose severe hazards to Canadians' health and safety or are thought unethical or inconsistent with Canadian values. The market for vitrification in North America would experience significant expansion due to such supportive government initiatives to encourage AHR procedures and the elevated risk of infertility.
The US market dominated the North America Vitrification Market, By Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $5,680.6 million by 2030. The Canada market is experiencing a CAGR of 19.4% during (2023 - 2030). Additionally, The Mexico market would exhibit a CAGR of 18.4% during (2023 - 2030).
Based on Specimen, the market is segmented into Oocytes (Devices, Kits & Consumables), Embryo (Devices, Kits & Consumables), and Sperm. Based on End-use, the market is segmented into IVF Clinics, and Biobanks. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Vitrolife AB, Genea Limited (Liverpool Partners Group), NidaCon International AB, Minitüb GmbH, Cryo Bio System (IMV Technologies Group), CooperSurgical Fertility & Genomic Solutions (The Cooper Companies, Inc.), FUJIFILM Irvine Scientific, Inc. (Fujifilm Holdings Corporation), Biotech, Inc., Kitazato Corporation and Shenzhen VitaVitro Biotech
Embryos and eggs are preserved for future use through vitrification when frozen. Techniques for vitrifying cells and tissues help preserve them, and they have a variety of applications in reproductive biology or regenerative medicine. It is employed, among other things, in preserving human fertility, storing cells for cell therapy, tissue regeneration, and gamete and embryo banking.
The need for assisted reproductive technologies (ARTs), a greater understanding of reproductive health issues, and an increase in service providers providing vitrification services are all expected to fuel the expansion of the market. This cryopreservation approach has become more effective because of its advantages over traditional slow-cooling methods. Additionally, given the current situation, most IVF facilities choose it because of its dependability and higher output.
The improvement of methods for preserving fertility sparked the creation of vitrification. This cutting-edge technique offers specimen preservation alternatives by reducing cryoprotectant exposure and shortening the preservation period. As a result, the market has seen profitable revenue growth. This has increased the widespread usage of vitrification devices. Delaying parenting is generally associated with sociodemographic factors, such as career and educational objectives, the growing influence of women's empowerment campaigns, the absence of a spouse, and financial constraints.
The Census Bureau said that between 1990 and 2019, the fertility rates in the United States steadily decreased. There were roughly 70.77 births per year for every 1,000 women aged between 15 to 44 in 1990. In that age group in 2019, there were approximately 58.21 births per 1,000 women. Further, the statistics showed that throughout the roughly 30-year period, the fertility rates of women aged 20 to 24 decreased by 43%, while those aged 35 to 39 soared by 67%. The AHR Act accomplishes this by outlining prohibited acts linked to aided human reproduction that could pose severe hazards to Canadians' health and safety or are thought unethical or inconsistent with Canadian values. The market for vitrification in North America would experience significant expansion due to such supportive government initiatives to encourage AHR procedures and the elevated risk of infertility.
The US market dominated the North America Vitrification Market, By Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $5,680.6 million by 2030. The Canada market is experiencing a CAGR of 19.4% during (2023 - 2030). Additionally, The Mexico market would exhibit a CAGR of 18.4% during (2023 - 2030).
Based on Specimen, the market is segmented into Oocytes (Devices, Kits & Consumables), Embryo (Devices, Kits & Consumables), and Sperm. Based on End-use, the market is segmented into IVF Clinics, and Biobanks. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Vitrolife AB, Genea Limited (Liverpool Partners Group), NidaCon International AB, Minitüb GmbH, Cryo Bio System (IMV Technologies Group), CooperSurgical Fertility & Genomic Solutions (The Cooper Companies, Inc.), FUJIFILM Irvine Scientific, Inc. (Fujifilm Holdings Corporation), Biotech, Inc., Kitazato Corporation and Shenzhen VitaVitro Biotech
Scope of the Study
Market Segments Covered in the Report:
By Specimen- Oocytes
- Devices
- Kits & Consumables
- Embryo
- Devices
- Kits & Consumables
- Sperm
- IVF Clinics
- Biobanks
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- Vitrolife AB
- Genea Limited (Liverpool Partners Group)
- NidaCon International AB
- Minitüb GmbH
- Cryo Bio System (IMV Technologies Group)
- CooperSurgical Fertility & Genomic Solutions (The Cooper Companies, Inc.)
- FUJIFILM Irvine Scientific, Inc. (Fujifilm Holdings Corporation)
- Biotech, Inc.
- Kitazato Corporation
- Shenzhen VitaVitro Biotech
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market At a Glance
Chapter 3. Market Overview
Chapter 4. North America Vitrification Market, By Specimen
Chapter 5. North America Vitrification Market, By End-use
Chapter 6. North America Vitrification Market, By Country
Chapter 7. Company Profiles
Companies Mentioned
- Vitrolife AB
- Genea Limited (Liverpool Partners Group)
- NidaCon International AB
- Minitüb GmbH
- Cryo Bio System (IMV Technologies Group)
- CooperSurgical Fertility & Genomic Solutions (The Cooper Companies, Inc.)
- FUJIFILM Irvine Scientific, Inc. (Fujifilm Holdings Corporation)
- Biotech, Inc.
- Kitazato Corporation
- Shenzhen VitaVitro Biotech
Methodology
LOADING...
